Roche AG: FDA clears Accu Check Inform II, Roche’s new hospital point of care system for blood glucose.
October 16, 2012 | by F. Hoffmann-La Roche AG
Reading time: 2 minutes
October 16, 2012, Testing with improved accuracy and wireless data transfer Next generation system also brings advances in patient care and durability. Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for the ACCU-CHEK Inform II system, a next generation blood glucose monitor for hospital point of care testing.
The ACCU-CHEK Inform II system offers healthcare professionals the first truly wireless hospital blood glucose device. The system utilizes new patented technology to deliver improved accuracy and enables automatic real time wireless transfer of patient data between hospital medical staff and the laboratory.
“Accuracy and patient safety are the foremost concerns for blood glucose testing in hospitals and other point of care settings,” said Roland Diggelmann, chief operating officer at Roche Diagnostics. “ACCU-CHEK systems have been proven in hospitals around the world and this next generation wireless system sets a new standard by offering U.S. healthcare professionals new capabilities to help ensure the accuracy of test results, streamline data communications and provide optimal patient care.”
The US is the world’s key market in hospital blood glucose testing. In 2011 a total of 25.8 million adults and children in the U.S. suffered from diabetes. This is roughly a tenth of the U.S. population.
The system is expected to be available in the U.S. beginning in October 2012.
Media Contact:
F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel BS Tel.: 061 688 11 11 Fax: 061 691 93 91
Editor's note: Image rights belong to the respective publisher.
Conclusion of this article: « Roche AG: FDA clears Accu Check Inform II, Roche’s new hospital point of care system for blood glucose. »
Source: F. Hoffmann-La Roche AG, Press release